Expression of cell regulatory proteins in ovarian borderline tumors

Cancer

Volumn 77, Issue 10, 1996, Pages 2092-2098

  Van Haaften Day, Caroline ^a   Russell, Peter ^b   Boyer, Cinda M ^c   Kerns, Billie Jo M ^e   Wiener, Jon R ^d   Jensen, Debra N ^a   Bast Jr , Robert C ^d   Hacker, Neville F ^a  

^a ROYAL HOSPITAL FOR WOMEN   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c DUKE CANCER INSTITUTE   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e BD Technologies   (United States)

Author keywords

EGFR; epithelial ovarian tumors; HER 2 neu; p53; protein tyrosine phosphatase

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE; REGULATOR PROTEIN;

ARTICLE; BENIGN TUMOR; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MUCINOUS CARCINOMA; ONCOGENE NEU; OVARY CARCINOMA; OVARY TUMOR; PRIORITY JOURNAL; PROTO ONCOGENE;

CARCINOMA; CELL CYCLE PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OVARIAN NEOPLASMS; PHENOTYPE; PROTEIN-TYROSINE-PHOSPHATASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029964448     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960515)77:10<2092::AID-CNCR19>3.0.CO;2-Q     Document Type: Article

References (40)

1. Boring CC, Squires TS, Tong T. Cancer statistics. CA Cancer J Clin 1992;42:19-38.
2. Cancer in New South Wales. Incidence in mortality. Sydney: NSW Cancer Council, 1992.
3. Scully RE. Common epithelial tumors of borderline malignancy (carcinomas of low malignant potential). Bull Cancer (Paris) 1982;69:228-38.
4. Russell P. Borderline epithelial tumours of the ovary: a conceptual dilemma. Clin Obstet Gynaecol 1984;11:259-78.
5. Russell P, Bannatyne P. Introduction to Mullerian epithelial and mesenchymal tumours. In: Surgical pathology of the ovaries. Edinburgh: Churchill Livingstone, 1989;190-216.
6. Bast RC Jr. Perspectives on the future of cancer markers. Clin Chem 1993;39:2444-51.
7. Bast RC Jr, Boyer CM, Jacobs I, Xu FJ, Wu S, Wiener J, et al. Cell growth regulation in epithelial ovarian cancer. Cancer 1993;71:1597-1601.
8. Carpenter G. Properties of the receptor for epidermal growth factor. Cell 1984;37:357-8.
9. Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, et al. The neu oncogene: an erb-B-related gene encoding a 185,000 - Mr tumor antigen. Nature 1984; 312:513-16.
10. Holmes WE, Slinkowski MX, Akita RW, Henzel WJ, Lee J, Park JW, et al. Identification of herequlin, a specific activator of p185 erb-B2. Science 1992;256:1205-10.
11. Peles E, Bacus SS, Koski RA, Lu HS, Wen D, Ogden SG, et al. Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell 1992;69:205-16.
12. Rodriguez GC, Berchuck A, Whitaker RS, Schlossman D, Clarke-Pearson DL, Bast RC Jr. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor and response to epidermal growth factor. Am J Obstet Gynecol 1991;164:745-50.
13. Berchuck A, Rodriguez GC, Kamel A, Dodge RK, Soper JT, Clarke-Pearson DL, et al. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am J Obstet Gynecol 1991;164:669-74.
14. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990;50:4087-91.
15. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keirh DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
16. Brown-Shimer S, Johnson KA, Lawrence JB, Johnson C, Bruskin A, Green NR, et al. Molecular cloning and chromosome mapping of the human gene encoding protein phosphotyrosyl phosphatase 1B. Proc Natl Acad Sci USA 1990;87:5148-52.
17. Frangioni JV, Beahm PH, Shifrin V, Jost CA, Neel BG. The nontransmembrane tyrosine phosphatase PTP-1B localizes to the endoplasmic reticulum via its 35 amino acid C-terminal sequence. Cell 1992;68:545-60.
18. Wiener JR, Hurteau JA, Kerns B, Whitaker BS, Conaway MR, Berchuck A, et al. Overexpression of the tyrosine phosphatase PTP1B is associated with human ovarian carcinomas. Am J Obstet Gynecol 1994;170:117-183.
19. Rogel A, Popliker M, Webb CG, Oren M. P53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos and tumors. Mol Cell Biol 1985;5:2851-5.
20. Lane D. P53, guardian of the genome. Nature 1992;358:15-6.
21. Vogelstein B, Kinzler KW. P53 function and dysfunction. Cell 1992;70:523-6.
22. Levine AJ, Perry ME, Chang A, Silver D, Dittmer D, Wu M, et al. The 1993 Walter Hubert lecture: The role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer 1994;69:409-16.
23. Berchuck A, Kohler MF, Marks JR, Wiseman R, Boyd J, Bast RC Jr. The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol 1994;170:247-52.
24. Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, et al. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 1991;51:2979-84.
25. Russell P. The surface epithelial-stromal tumors of the ovary. In: Kurman RJ, editor. Blaustein's pathology of the female genital tract. 4th edition. New York: Springer-Verlag, 1994: 705-83.
26. van Haaften-Day C, Russell P, Brammah-Carr S. Two homologous mixed mullerian tumor lines of the ovary and their characteristics. Cancer 1990;65:1753-61.
27. Kerns B-JM, Jordan PA, Huper G, Marks JR, Iglehart JD, Layfield LJ. Assessment of c-erb B-2 amplification by immunohistochemistry in paraffin embedded breast cancer. Mod Pathol 1993;6:673-8.
28. Sternberger LA, Hardy PA, Cuculis JJ, Meyer HG. The unlabelled antibody enzyme method immunohistochemistry. J Histochem Cytochem 1970;18:315-33.
29. Eccles DM, Brett L, Lessells A, Gruber L, Lane D, Steel CM, et al. Overexpression of the p53 protein and allele loss at 17 p13 in ovarian carcinoma. Br J Cancer 1992;65:40-4.
30. Teneriello MG, Ebina M, Linnoila RI, Henry M, Nash JD, Park RC, et al. P53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res 1993;53:3103-8.
31. Renninson J, Baker BW, McGown AT, Murphy D, Norton JD, Fox BW, et al. Immunohistochemical detection of mutant p53 protein in epithelial ovarian cancer using polyclonal antibody CMI: correlation with histopathology and clinical features. Br J Cancer 1994;69:609-12.
32. Henzen-Logmans SC, Fieret EJH, Berns EMJJ, van der Burg MEL, Klijn JGM, Foekens JA. Ki-67 staining in benign, borderline, malignant primary and metastatic ovarian tumors: correlation with steroid receptors, epidermal-growth factor receptor and cathepsin D. Int J Cancer 1994;57:468-72.
33. Stromberg K, Johnson GR, O'Connor DM, Sorensen CM, Gullick WJ, Kannan B. Frequent immunohistochemical detection of EGF supergene family members in ovarian carcinogenesis. Int J Gynecol Pathol 1994;13:342-7.
34. Kacinski BM, Mayer AG, King BL, Carter D, Chambers SK. Neu protein overexpression in benign, borderline and malignant ovarian neoplasms. Gynecol Oncol 1992;44:245-53.
35. Seidman JD, Frisman DM, Dorris HJ. Expression of the HER-2/neu proto-oncogene in serous ovarian neoplasms. Cancer 1992;70:2857-60.
36. Rubin SC, Finstad CL, Federici BS, Scheiner L, Lloyd KO, Hoskins WJ. Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer. Cancer 1994;73: 1456-9.
37. Midgley CA, Fisher CJ, Bartek J, Vojtesek B, Lane D, Barnes DM. Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli. J Cell Sci 1992;101:183-189.
38. Maestro R, Dolcetti R, Gasparotto D, Doglioni C, Peluchi S, Barzan L, et al. High frequency of p53-gene alteration associated with protein over-expression in human squamous-cell carcinoma of the larynx. Oncogene 1992;7:1159-66.
39. Wynford TD. p53 in tumour pathology: can we trust immunohistochemistry? [editorial]. J Pathol 1992;166:331-2.
40. van Haaften-Day C, Russell P, Davies S, Brammah-Carr S. An in vitro study of ovarian atypical proliferating (borderline) serous tumors. Int J Gynecol Cancer 1992;2:41-8.